USFDA nod to Leqembi IV maintenance dosing for treatment of early Alzheimer's Disease: Eisai, Biogen Ruchika Sharma27 Jan 2025 12:22 PM ISTTokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental...
Merck, Eisai to shut down late stage study for combo cancer therapy Ruchika Sharma28 Aug 2023 12:31 PM ISTThe companies are testing the combination to treat a range of cancers, including those affecting the lungs and stomach.
USFDA grants traditional approval for Eisai Leqembi for Alzheimer's disease treatment Ruchika Sharma7 July 2023 1:30 PM ISTStockholm:BioArctic AB's (publ)partner Eisai has announced that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics...
Eisai seeks marketing nod for Lecanemab for early Alzheimer's disease treatment in South Korea Ruchika Sharma11 Jun 2023 12:45 PM ISTLecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of...
USFDA advisory committee votes unanimously to confirm clinical benefit of Leqembi for Alzheimer's Disease Ruchika Sharma10 Jun 2023 1:30 PM ISTTokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System...
Eisai seeks marketing authorisation for Lecanemab to treat early Alzheimer's disease in Great Britain Ruchika Sharma23 May 2023 11:00 AM ISTLecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of...
USFDA advisers to weigh full nod for Eisai-Biogen Alzheimer's drug Leqembi Ruchika Sharma11 April 2023 10:00 AM ISTLeqembi belongs to a class of treatments that aim to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic protein...
Eisai dissolves joint venture with Bracco Imaging Ruchika Sharma21 Feb 2023 2:30 PM ISTItaly: Bracco Imaging S.p.A and Eisai Co., Ltd. have announced that the joint venture regarding the company Bracco-Eisai Co., Ltd., will be dissolved...
Eisai gets Japanese orphan drug designation for ultrahigh-dose mecobalamin with prospective indication for functional impairment of amyotrophic lateral sclerosis Ruchika Sharma30 May 2022 11:00 AM ISTALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron...
